Tango Therapeutics Stock (NASDAQ:TNGX)
Previous Close
$3.85
52W Range
$2.70 - $13.01
50D Avg
$6.53
200D Avg
$8.49
Market Cap
$438.27M
Avg Vol (3M)
$1.76M
Beta
0.88
Div Yield
-
TNGX Company Profile
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
TNGX Performance
Peer Comparison
Ticker | Company |
---|---|
PLRX | Pliant Therapeutics, Inc. |
NRIX | Nurix Therapeutics, Inc. |
KYMR | Kymera Therapeutics, Inc. |
ARVN | Arvinas, Inc. |
CGEM | Cullinan Oncology, Inc. |
RVMD | Revolution Medicines, Inc. Warrant |
FHTX | Foghorn Therapeutics Inc. |
MLYS | Mineralys Therapeutics, Inc. |
EWTX | Edgewise Therapeutics, Inc. |
STOK | Stoke Therapeutics, Inc. |
BDTX | Black Diamond Therapeutics, Inc. |
RLAY | Relay Therapeutics, Inc. |
BCEL | Atreca, Inc. |
RLYB | Rallybio Corporation |
TYRA | Tyra Biosciences, Inc. |
CNTB | Connect Biopharma Holdings Limited |
PASG | Passage Bio, Inc. |
GLUE | Monte Rosa Therapeutics, Inc. |
XLO | Xilio Therapeutics, Inc. |
THRD | Third Harmonic Bio, Inc. |
STTK | Shattuck Labs, Inc. |
RAPT | RAPT Therapeutics, Inc. |